Latest news with #NeilJohnson
Yahoo
28-05-2025
- Business
- Yahoo
Long-term Commitment to Treating Endometriosis and Improving Women's Quality of Life - Gedeon Richter at the World Congress on Endometriosis
SYDNEY, May 28, 2025 /PRNewswire/ -- Gedeon Richter had a strong presence at the World Congress of Endometriosis held this year in Sydney, Australia between 21-24 May 2025. As a Platinum Sponsor Gedeon Richter could reaffirm its innovation driven and long-term commitment in the field of endometriosis and in women's health. The company hosted a highly successful symposium titled Delving into Endometriosis Pain Management: From Adolescence to Family Planning, chaired by Prof. Neil Johnson. The session featured Prof. Rebecca Deans (Australia) on the early management of endometriosis in adolescence, Prof. Jason Abbott (Australia) on pain control and quality of life in adulthood, and Prof. Juan García-Velasco (Spain) on fertility challenges and family planning. This comprehensive agenda reflects Gedeon Richter's focus on two closely linked areas, endometriosis and infertility, and its dedication to supporting women. Besides the expert-led scientific symposium, Gedeon Richter's booth showcased the medical options offered for the management of endometriosis in the exhibition area as well. Being Platinum Sponsors of WCE enabled us to show our dedication to endometriosis care with holistic, patient-centric mindset addressing both physical and emotional dimensions of women's health. Endometriosis is a chronic, painful condition affecting over 190 million women worldwide, with an ever-increasing prevalence rate. It occurs when tissue similar to the lining of the uterus grows outside the uterine cavity, leading to inflammation, scarring, and significant pain. Beyond physical discomfort, endometriosis can seriously impact fertility and overall quality of life, requiring effective medical treatment. Gedeon Richter markets the first and only globally available Relugolix combination therapy, for the treatment of moderate to severe symptoms of uterine fibroids and symptomatic endometriosis. This GnRH antagonist combines multiple active ingredients to effectively target the disease mechanism, offering symptom relief in a once-daily oral therapy. Its convenience, safety and proven efficacy allows women to manage their conditions without resorting to surgery. "As one of Europe's leading pharmaceutical companies in the women's healthcare segment, Gedeon Richter is committed to providing modern and progressive solutions on a global scale. We believe that the continuous development of therapeutic options, such as our innovative medicine for endometriosis and our fertility products, will enable millions of women around the world to improve their quality of life," said Dr. Peter Turek, Global Head of Gedeon Richter's Women's Healthcare Business Unit. View original content: SOURCE Gedeon Richter Plc.
Korea Herald
01-05-2025
- Health
- Korea Herald
Preserving fertility and optimising care for the one in seven women suffering from endometriosis
SINGAPORE, May 1, 2025 /PRNewswire/ -- Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to help preserve the fertility of those with the debilitating condition. They have finalised a rigorous consensus process to create a defined and auditable standard for networks of expertise for endometriosis treatment for the one in seven females of reproductive age living with the chronic pelvic pain and fertility risk from the disease. It sets a gold standard of patient-centred care for sufferers of endometriosis and a similar condition called adenomyosis while considering the diversity of countries, economies, cultures and societies in the APAC region. The experiences and views of patients living with endometriosis and adenomyosis have been incorporated in developing the consensus structure. Endometriosis occurs when tissue similar to the inner lining of the uterus grows outside the uterus. It often affects the ovaries, fallopian tubes and the tissue lining the pelvis. Currently, there is no absolute preventive strategy or cure for the condition, but treatment options can help manage its chronic impacts. The new approaches to endometriosis treatment will be outlined this week at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore. The Congress from today (1 May) to Sunday has brought together over 2,000 scientists, clinicians, nurses and counsellors for a program that will help shape the future of fertility health care in the region and around the world. New Zealand fertility specialist Professor Neil Johnson, an ASPIRE Board member and Past President of the World Endometriosis Society, has led the endometriosis consensus program with international specialists in the field. "The topics covered and the way that they have been addressed set new world standards in care, and our hope is that they will influence policy makers and those responsible for health funding decisions," Professor Johnson explained. "My aspiration for the networks of expertise consensus is that it presents what our APAC experts believe to be the optimal model of how complex multidisciplinary care in endometriosis should be best structured. "Currently, there is a wide variation in the quality of multidisciplinary care for endometriosis. In many settings, care is provided without the key structures and enmeshment that is crucial for coordinated patient care. "This consensus has the potential to become an accreditation gold standard. It may then be possible to assess the calibre of endometriosis care services across APAC to determine whether they meet the ASPIRE standard to be defined as a network of expertise. "The consensus on fertility preservation in endometriosis is an issue that has come into sharp focus. In the past, repeated ovarian surgery for endometriosis sufferers has meant that some patients have ended up with extremely low ovarian reserve, which refers to the quantity of eggs remaining in the ovaries with egg quality often negatively affected by endometriosis. "In some cases, ovarian reserve has become so low that it is very difficult for these patients to achieve a pregnancy either through natural conception or medically assisted reproduction. This is a tragic outcome for young women. "Our consensus emphasises the need for awareness that endometriosis itself can compromise ovarian reserve along with the impact of ovarian surgery. "It highlights the importance of blood testing for anti-mullerian hormone (AMH) levels and ovarian ultrasound for antral follicle count to accurately measure a patient's ovarian reserve. "Timing of pregnancy is another important consideration. While it is a personal choice, the ability to conceive may be affected by a decision to delay attempts to become pregnant. "Of prime importance is the provision of information on fertility preservation to endometriosis sufferers no later than in their twenties. This is vital for patients with severe (stage IV) endometriosis or those facing ovarian surgery. "Fertility preservation is typically through egg freezing, although embryo freezing might be preferred by some couples in committed relationships. "Ovarian tissue freezing may be considered in exceptional cases for endometriosis. Typically, this is an option for cancer patients facing potentially sterilising chemotherapy in the oncology setting. However, more research is needed to explore the role of ovarian tissue freezing for those with endometriosis. "Finally, our consensus teams highlight the importance of integrating psychological support and overall fertility counselling as a critical aspect of care. The ASPIRE 2025 Congress is being held at the Suntec Convention and Exhibition Centre in Singapore. For further information, go to
